{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:33:45Z","timestamp":1761744825077,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.dsx.2020.07.041","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T12:13:13Z","timestamp":1595592793000},"page":"1401-1402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Commentary on \u201cangiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic\u201d"],"prefix":"10.1016","volume":"14","author":[{"given":"Carlos M.","family":"Ferrario","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.dsx.2020.07.041_bib1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.dsx.2020.04.019","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic","volume":"14","author":"Cure","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"17","key":"10.1016\/j.dsx.2020.07.041_bib2","doi-asserted-by":"crossref","first-page":"14838","DOI":"10.1074\/jbc.M200581200","article-title":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase","volume":"277","author":"Vickers","year":"2002","journal-title":"J\u00a0Biol Chem"},{"issue":"20","key":"10.1016\/j.dsx.2020.07.041_bib3","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.dsx.2020.07.041_bib4","doi-asserted-by":"crossref","first-page":"H2166","DOI":"10.1152\/ajpheart.00061.2006","article-title":"Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats","volume":"291","author":"Jessup","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"10.1016\/j.dsx.2020.07.041_bib5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1291\/hypres.31.553","article-title":"Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade","volume":"31","author":"Igase","year":"2008","journal-title":"Hypertens Res"},{"issue":"3","key":"10.1016\/j.dsx.2020.07.041_bib6","doi-asserted-by":"crossref","first-page":"H1013","DOI":"10.1152\/ajpheart.00068.2005","article-title":"Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats","volume":"289","author":"Igase","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"10.1016\/j.dsx.2020.07.041_bib7","first-page":"125","article-title":"Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy","volume":"3","author":"Schindler","year":"2007","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"10.1016\/j.dsx.2020.07.041_bib8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0895-7061(97)00400-7","article-title":"Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects","volume":"11","author":"Ferrario","year":"1998","journal-title":"Am J Hypertens"},{"issue":"4","key":"10.1016\/j.dsx.2020.07.041_bib9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0196-9781(93)90097-Z","article-title":"Cardiovascular actions of angiotensin(1-7)","volume":"14","author":"Benter","year":"1993","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.dsx.2020.07.041_bib10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/angiotensin-(1-7)\/MAS Axis of the renin-angiotensin system: focus on angiotensin-(1-7)","volume":"98","author":"Santos","year":"2018","journal-title":"Physiol Rev"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402120302885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402120302885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:13:48Z","timestamp":1761729228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402120302885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1871402120302885"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2020.07.041","relation":{},"ISSN":["1871-4021"],"issn-type":[{"type":"print","value":"1871-4021"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Commentary on \u201cangiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic\u201d","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2020.07.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}